ALX Oncology Holdings Inc.
ALXO
NASDAQ·Healthcare·Biotechnology·Mkt cap $279.9M
$2.03
▼ -2.40%
P/E
-1.57
Mkt Cap
$279.9M
52-Wk Range
$0.99–$2.66
52-Week Range
$0.99 - $2.66
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 103.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel CD47 blocking mechanism addressing immune evasion in cancer
- Strategic partnerships with Merck, Zymeworks, and Tallac Therapeutics
- Multi-indication pipeline covering blood cancers and solid tumors
- Advanced SIRPa TRAAC platform engaging innate and adaptive immunity
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Phase 1b/2 clinical trial progression and positive data readouts
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+24.6% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ALXO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.13 vs -$0.14 consensus (+9.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+9.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Mar 10, 2026
vs Industry
How ALXO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related